Clasificación en acciones
#22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Precio por acción
$0.04959193
Última sincronización: 2025-03-17
Capitalización bursátil
$79.94M
Comercio Abliva AB (publ) (ABLI)
Precio ABLI con Capital del mercado a B
Capitalización de mercado de Abliva AB (publ)(ABLI)
Capitalización bursátil: $79.94M
A fecha de August 2026, Abliva AB (publ) tiene una capitalización de mercado de $79.94M. Esto convierte a Abliva AB (publ) en la 22998th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Abliva AB (publ) desde 2008 hasta 2026
ABLI en comparación con los más populares 5 títulos stocks
| Precio por ABLI |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.211T
|
+6,519,334.37%
|
|
|
|
|
$4.547T
|
+5,687,889.61%
|
|
|
|
|
$4.162T
|
+5,207,166.93%
|
|
|
|
|
$3.593T
|
+4,494,489.39%
|
|
|
|
|
$2.793T
|
+3,493,767.13%
|
